Senti Biosciences (NASDAQ:SNTI) & PTC Therapeutics (NASDAQ:PTCT) Head-To-Head Contrast

Senti Biosciences (NASDAQ:SNTI) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.

Insider & Institutional Ownership

25.7% of Senti Biosciences shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 5.3% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Senti Biosciences and PTC Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20,000.00	518.02	-$61.44 million	($1.77)	-0.19
PTC Therapeutics	$1.01 billion	5.73	$682.64 million	($0.58)	-119.48

PTC Therapeutics has higher revenue and earnings than Senti Biosciences. PTC Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Senti Biosciences has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.

Profitability

This table compares Senti Biosciences and PTC Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-1,629.80%	-119.72%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Senti Biosciences and PTC Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1	0	2	1	2.75
PTC Therapeutics	2	2	9	1	2.64

Senti Biosciences currently has a consensus price target of $10.00, indicating a potential upside of 2,906.61%. PTC Therapeutics has a consensus price target of $98.55, indicating a potential upside of 42.20%. Given Senti Biosciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Senti Biosciences is more favorable than PTC Therapeutics.

About Senti Biosciences

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About PTC Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.